Erratum: Predicting time to ovarian carcinoma recurrence using protein markers (Journal of Clinical Investigation (2013) 123:9 (3740-3750) DOI: 10.1172/JCI68509);Predicting time to ovarian carcinoma recurrence using protein markers

Journal of Clinical Investigation

Volumn 123, Issue 9, 2013, Pages 3740-3750

  Yang, Ji Yeon ^a   Yoshihara, Kosuke ^a,b   Tanaka, Kenichi ^b,c   Hatae, Masayuki ^d   Masuzaki, Hideaki ^e   Itamochi, Hiroaki ^f   Takano, Masashi ^g   Ushijima, Kimio ^h   Tanyi, Janos L ⁱ   Coukos, George ⁱ   Lu, Yiling ^a   Mills, Gordon B ^a   Verhaak, Roel G W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c Niigata Medical Center Hospital   (Japan)

^d Kagoshima City Hospital   (Japan)

^e NAGASAKI UNIVERSITY   (Japan)

^f TOTTORI UNIVERSITY   (Japan)

^g NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^h KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN KINASE C; TUMOR MARKER; VASCULOTROPIN RECEPTOR; TRANSCRIPTOME; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SHORT TERM SURVIVAL; CLUSTER ANALYSIS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM; OVARY TUMOR; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEOMICS; RISK; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEOMICS; RISK; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84883528065     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74035     Document Type: Erratum

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Kobel M, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29(3):203-211.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
4. Coleman MP, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377(9760):127-138.
5. Winter WE 3rd, et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(24):3621- 3627.
6. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234-1244.
7. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183-203.
8. Agarwal R, Kaye SB. Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol. 2005;16(1):4-6. (Pubitemid 40124469)
9. Yoshihara K, et al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res. 2012;18(5):1374-1385.
10. Konstantinopoulos PA, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28(22):3555-3561.
11. Kang J, D'Andrea AD, Kozono D. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst. 2012;104(9):670-681.
12. Verhaak RGW, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013;123(1):517-525.
13. Tibes R, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006;5(10):2512-2521. (Pubitemid 44650915)
14. Tabchy A, Hennessy BT, Gonzalez-Angulo AM, Bernstam FM, Lu Y, Mills GB. Quantitative proteomic analysis in breast cancer. Drugs Today (Barc). 2011;47(2):169-182.
15. Zhang Y, Rajapakse JC. Machine Learning In Bioinformatics. Hoboken, New Jersey, USA: John Wiley & Sons, Inc.; 2008.
16. Cancer Genome Atlas Research Network, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
17. Harris MA, et al. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2004;32(Database issue):D258-D261. (Pubitemid 38081651)
18. Nakakuki T, Ide K, Yumoto N, Nagashima T, Hatakeyama M. In silico simulation of epidermal growth factor signaling in prostate cancer cells. Presented at: Genomic Signal Processing and Statistics, 2007. GENSIPS 2007. IEEE International Workshop; June 2007.
19. Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol. 2005;1:2005.008.
20. Katsumata N, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331-1338.
21. Burger RA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-2483.
22. Perren TJ, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484-2496.
23. Kim DC, Wang X, Yang CR, Gao JX. A framework for personalized medicine: prediction of drug sensitivity in cancer by proteomic profiling. Proteome Sci. 2012;10(suppl 1):S13.
24. Donoho DL. High-dimensional data analysis: The curses and blessings of dimensionality. Presented at: Aide-Memoire of a Lecture at AMS Conference on Math Challenges of the 21st Century; August 2000; Los Angeles, California, USA.
25. Zou H, Hastie T, Tibshirani R. On the "degrees of freedom" of the lasso. Ann Statist. 2007;35(5):2173-2192.
26. Yuan M, Lin Y. Model selection and estimation in regression with grouped variables. J R Stat Soc Ser B Stat Methodol. 2006;68(1):49-67. (Pubitemid 43415335)
27. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238-244. (Pubitemid 41043794)
28. Elattar A, et al. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol. 2012;124(1):142-147.
29. Nodin B, et al. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res. 2010;3:14.
30. Li AJ, Scoles DR, Armstrong KU, Karlan BY. Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas. Gynecol Oncol. 2008;109(2):220-225.
31. Prat A, et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol. 2012;23(11):2866-2873.
32. Farley J, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14(2):134-140.
33. Bartholomeusz C, et al. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther. 2012;11(2):360-369.
34. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21(2):283-290. (Pubitemid 46606157)
35. Carey MS, et al. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res. 2010;16(10):2852-2860.
36. Yang JY, He X. A multistep protein lysate array quantification method and its statistical properties. Biometrics. 2011;67(4):1197-1205.
37. Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, Mills GB. Non-parametric quantification of protein lysate arrays. Bioinformatics. 2007;23(15):1986-1994. (Pubitemid 47299840)
38. Hennessy BT, et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics. 2010;6(4):129-151.
39. Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for Cox's proportional hazards model via coordinate descent. J Stat Softw. 2011;39(5):1-13.
40. Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B Stat Methodol. 1994;58:267-288.
41. Zou H. A note on path-based variable selection in the penalized proportional hazards model. Biometrika. 2008;95(1):241-247. (Pubitemid 351333336)
42. Yang D, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011;306(14):1557-1565.
43. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14(5):1291-1295. (Pubitemid 351413906)
44. Tothill RW, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198- 5208.
45. Marquez RT, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005;11(17):6116-6126. (Pubitemid 41262937)
46. Al-Shahrour F, Minguez P, Vaquerizas JM, Conde L, Dopazo J. BABELOMICS: a suite of web tools for functional annotation and analysis of groups of genes in high-throughput experiments. Nucleic Acids Res. 2005;33(Web Server issue):W460-W464.
47. Al-Shahrour F, et al. BABELOMICS: a systems biology perspective in the functional annotation of genome-scale experiments. Nucleic Acids Res. 2006;34(Web Server issue):W472-W476.
48. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
49. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol. 1995;57(1):289-300.
50. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Statist. 2001;29(4):1165-1188. (Pubitemid 33575263)